Every day a trial runs late costs its sponsor somewhere between $600,000 and $8 million in lost revenue, depending on the market opportunity of the drug candidate, and the clock on premium pricing does not stop while the study catches up. Most teams plan for slow enrollment. Far fewer plan for the participants who join, then quietly stop taking the study drug. That second problem is the one this article is about.
Several activities feed a clinical trial budget: per-participant costs (recruitment and retention), study site costs (investigator fees, site staff and administrative fees, IRB fees, procedure fees), and per-study fees (data collection, monitoring, sponsor and CRO personnel salaries, protocol amendments, and vendor costs). Timeline slippage inflates all of them. It also means roughly $600,000 per day in lost revenue opportunity for niche products, and up to $8 million per day for blockbuster medical products.
It would be ideal if every participant adhered to the investigational medicinal product (IMP) and the study protocol. Many do not. Approximately 40% of participants become non-adherent to IMP after 150 days in a clinical trial, which not only causes temporary bouts of toxicity (double dosing) and lack of efficacy (skipping doses), but also introduces data variability into the equation.
Increases in data variability mean that study teams need to enroll more participants to achieve the study’s statistical outcomes. It is important to emphasize that linear increases in non-adherence have an exponential impact on the number of participants needed to yield the same statistical outcome. A 20% to 30% IMP non-adherence rate requires a 50% increase in the study’s sample size to maintain equivalent statistical power; once non-adherence reaches 50%, the sample size needs to increase by 200%. Yet discussion among industry professionals suggests that study scientists do not factor non-adherence into trial design.
Non-adherence leads to enrolling more participants to achieve the same statistical outcomes, increases timeline slippage, and elevates operational costs. On average across all therapeutic indications, a Phase III trial needs to enroll an additional 460 participants (totaling 828) to maintain equivalent statistical power, assuming a constant 40% IMP non-adherence rate. The operational cost to enroll 460 participants is estimated at $12 million. Reducing IMP non-adherence by 1% (to 39%) means sponsors need to enroll 13 fewer participants to maintain equivalent statistical power, saving approximately $336K and, naturally, minimizing timeline slippage.
This analysis shows only one form of study non-adherence (IMP non-adherence), which has a direct impact on data variability and statistical outcomes. Combined with other forms of non-adherence (dropout, incomplete ePRO questionnaires, missed study visits, and not following study procedures), further study prolongation follows.
Assessing Adherence to Strengthen Trial Results
Participants need to follow the protocol as written for a trial’s results to be reliable. Adherence directly affects data integrity and influences the validity of study conclusions and regulatory approval. Without consistent adherence, even well-designed trials can produce misleading outcomes and compromise the value of research.
Poor adherence is caused by complex dosing schedules, logistical burdens, and lack of support, among other factors. Low adherence makes efficacy signals harder to detect and leads to inconclusive or inaccurate findings. Adherence in clinical trials improves with practical interventions that reduce deviations, so results reflect the true effect of the treatment.
Understanding Barriers to Adherence
Adherence is influenced by study complexity, how well participants understand what is being asked of them, and external pressures. Participants struggling with complicated medication regimens or frequent site visits may unintentionally deviate from the protocol. Some may forget doses, while others discontinue treatment due to side effects, lack of perceived benefit, or external stress.
Financial, logistical, and psychological burdens also affect adherence. Trials that do not consider these realities see high dropout rates or non-compliance, their statistical power is reduced, and their treatment effects are distorted. Clear communication, simplified study requirements, and practical support show up as fewer missed doses, fewer missed visits, and fewer people leaving.
Education is key. People who understand why adherence matters, both for their own care and for the study’s findings, are more likely to stay compliant. Transparent discussions about expectations, risks, and benefits create a sense of partnership between researchers and participants. This is where understanding earlier pays off: a person who grasps what the protocol asks before they join is far less likely to discover at month five that it does not fit their life.
Adherence is also influenced by how well participants connect with trial staff. A supportive research team that prioritizes clear, empathetic communication builds better relationships with participants. People who feel heard and respected are more likely to follow study requirements consistently. This makes ongoing contact essential, including regular check-ins and personalized support plans.
Enhancing Monitoring for Patient Adherence Clinical Trials
Effective adherence monitoring requires a combination of technology, direct patient interaction, and data analysis. Passive monitoring tools, such as smart pill bottles and digital reminders, provide real-time adherence pattern reports. Electronic patient-reported outcomes (ePROs) show researchers early signs of non-adherence.
Regular visits and remote check-ins are touchpoints for participants to discuss challenges and receive support. A clear picture of compliance combines objective adherence measures with participant feedback. Participants who struggle with adherence can benefit from dose adjustments or additional counseling.
Integrating artificial intelligence (AI) into adherence monitoring is a growing area of interest. AI-driven models can analyze patient-reported data to predict potential adherence risks before they result in non-compliance. By flagging these risks early, trial teams can offer targeted support, helping participants stay on track while reducing data variability.
When adherence is systematically monitored, deviations can be identified and addressed promptly. This proactive approach minimizes missing data, strengthens the study, and improves the reliability of conclusions drawn from trial results.
Improving Trial Adherence With Designs Built Around People
Patient-friendly trial frameworks reduce adherence challenges. Flexible visit schedules, decentralized trial options, and home-based monitoring ease logistical burdens. Transportation assistance or delivery of products further helps participants maintain consistency.
Improving trial adherence is possible through digital tools that keep participants informed and reminded. Mobile apps, automated text reminders, and virtual check-ins reinforce study commitments and accommodate individual needs.
Personalization makes interventions more effective. Some participants benefit from motivational interviewing that identifies barriers and builds commitment, while others require structured support, such as coaching or simplified medication regimens.
Trial staff have a role in improving adherence. With proper training, research teams can respond effectively to participant concerns and improve retention and compliance. Trial teams that actively listen and adapt reduce dropout rates and strengthen study results, because participants are more likely to stay in the study and keep to the protocol.
Trial design that starts from participants’ lives minimizes unnecessary complexity. Researchers must balance scientific rigor with practical feasibility, ensuring that trials are both methodologically sound and accessible. This approach leads to higher retention rates, better data quality, and ultimately, more meaningful research outcomes.
Strengthening Data Integrity for Reliable Outcomes
Adherence is more than a measure of compliance. It is essential for generating high-quality data. Inconsistent adherence introduces variability, dilutes treatment effects and complicates data interpretation. When adherence rates drop, the accuracy of study conclusions also decreases, which in turn affects regulatory approval and clinical adoption.
A structured adherence strategy protects trial outcomes by ensuring data integrity. This involves standardizing adherence measurement methods across sites and using consistent reporting frameworks. By reducing variability, researchers can be more confident in their findings, leading to more robust regulatory submissions and clinical recommendations.
Proactively addressing adherence strengthens trial outcomes by reducing data inconsistencies and ensuring that study findings are accurate and generalizable. Investigators who prioritize adherence from study initiation set a foundation for reliable, actionable results. This not only benefits researchers but also improves the likelihood of bringing effective treatments to market.
Adherence strategies should not end with trial completion. Post-trial follow-up studies can provide additional insights into long-term adherence trends and inform future trial designs. Lessons learned from adherence monitoring in one study can enhance best practices for future clinical research.
Adherence problems often begin before day one, when someone joins a study they did not fully understand. trialport gives people a plain-language summary with medifit™ + readifit™ self-reflection tools before they contact a site, so the question “Is this trial right for my life?” is asked at the start rather than at month five. See what trialport does for sponsors and CROs.
About the author
Keith Berelowitz has spent more than twenty years watching clinical trials work on paper and struggle in real life. He has helped run studies, advises sponsors and CROs on how they engage with people, and chairs a UK research ethics committee, where consent forms and participant information sheets cross his desk every month. That vantage point led to one conclusion: most trial problems are not failures of science. They are failures of understanding at the moment a person decides.
He founded trialport, a clinical trial navigation and decision-support platform, so that understanding a study comes before anyone is asked to join one. Understanding comes first. Decisions follow.